NOT FOR DISTRIBUTION INTO THE UNITED STATES

The information contained in this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States.  The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, transferred, delivered or distributed, directly or indirectly, in any form, in or into, the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering or sale of securities in the United States will be made.

CELLBXHEALTH plc ("the Company")

Further Update on Funding

CELLBXHEALTH plc (AIM:CLBX), a global leader in circulating tumour cell (CTC) intelligence, announces, further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026.  CelLBxHealth has recently commenced discussions with a number of shareholders and is seeking to raise approximately £6m with the intention to make an offer to retail investors alongside an institutional placing.  

The Company expects to announce the fundraise by early December and will make further updates as appropriate.  

For further information:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 Notes for editors

About CelLBxHealth plc

CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales:  Accelerating Parsortix platform adoption and consumable sales through CROs* and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development.

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

For more information, visit https://cellbxhealth.com/.